Teva Pharmaceutical Industries (NYSE:TEVA) has been given a $13.00 price target by Royal Bank of Canada in a research note issued on Tuesday. The brokerage presently has a “sell” rating on the stock. Royal Bank of Canada’s target price would suggest a potential downside of 37.05% from the stock’s current price.
A number of other brokerages have also issued reports on TEVA. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Tuesday, January 23rd. Wells Fargo & Co reissued a “sell” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, January 22nd. Credit Suisse Group set a $20.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Monday, January 22nd. Leerink Swann lifted their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “underperform” rating in a research note on Friday. Finally, Mizuho reissued a “hold” rating and set a $16.00 target price on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 4th. Eight investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average price target of $21.81.
Teva Pharmaceutical Industries (TEVA) traded down $0.96 during midday trading on Tuesday, reaching $20.65. 17,895,500 shares of the company’s stock traded hands, compared to its average volume of 24,580,000. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $37.94. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The stock has a market cap of $20,950.00, a PE ratio of -3.52, a price-to-earnings-growth ratio of 1.55 and a beta of 0.54.
Several hedge funds have recently added to or reduced their stakes in the stock. Security National Bank of Sioux City Iowa IA lifted its position in Teva Pharmaceutical Industries by 0.4% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after acquiring an additional 87 shares during the last quarter. Bank of Nova Scotia lifted its position in Teva Pharmaceutical Industries by 8.3% during the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after acquiring an additional 528 shares during the last quarter. Security National Bank of SO Dak lifted its position in Teva Pharmaceutical Industries by 3.7% during the 2nd quarter. Security National Bank of SO Dak now owns 17,385 shares of the company’s stock worth $578,000 after acquiring an additional 620 shares during the last quarter. Caxton Associates LP lifted its position in Teva Pharmaceutical Industries by 6.6% during the 2nd quarter. Caxton Associates LP now owns 13,000 shares of the company’s stock worth $432,000 after acquiring an additional 800 shares during the last quarter. Finally, Salem Investment Counselors Inc. lifted its position in Teva Pharmaceutical Industries by 12.8% during the 2nd quarter. Salem Investment Counselors Inc. now owns 9,400 shares of the company’s stock worth $312,000 after acquiring an additional 1,068 shares during the last quarter. 51.88% of the stock is owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
